VCU Health Leads Clinical Trial For New treatment To Help People With Bowel Control Problems

A research team at VCU Health is leading a clinical trial to assess a novel treatment for fecal incontinence or sudden loss of control over bowel movements. The therapy involves implanting a bioengineered sphincter derived from the patient’s native cells to help them regain control of their bowels.  The implantation surgery for the clinical trial is being led by Jaime Bohl, M.D., an associate professor in the Department of Surgery and chief of the Division of Colon and Rectal Surgery at Virginia Commonwealth University’s School of Medicine. Read more.

Source: VCU Health, February 28, 2024

clinical medical

Cellf BIO Begins Phase 1 Clinical Trial of BioSphincter™ Implant for Fecal Incontinence

Cellf BIO, a biotechnology company that manufactures bioengineered sphincters using autologous progenitor cells, announced today that it has begun its Phase 1 clinical trial for its BioSphincter™ Implant for the treatment of severe passive fecal incontinence (FI). The FDA cleared the company’s Investigational New Drug (IND) application, and the Institutional Review Board (IRB) approved the trial to begin enrolling participants. Read more.

Source: Globe Newswire, January 5, 2023